The underlying molecular events involve augmented glucose uptake by cancer cells due to insulin-dependent translocation of glucose transporter GLUT4 to the plasma membrane, highlighting a previously unknown mechanism through which heparanase enzyme acts at the interface of systemic and intracellular metabolic alterations typical for PDAC. The gene discussed is HPSE; the disease is cancer.